Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Azithromycin for the Treatment of Yaws

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children 6 months to 15 years of age who present to LMC with suggestive skin lesions or joint pains and VDRL and TPHA testing are positive~* Suggestive skin lesions defined as: Symptomatic \> 4 weeks, painless, a traumatic ulcers with raised margins. VDRL positive when titer of at least 1:16~Exclusion Criteria:~* Pregnancy~* Less than 6 months of age~* Known allergy to penicillin or macrolide~* Use of antibiotics active against treponema during the preceding six months (penicillin-G-benzathine, ceftriaxone, azithromycin or doxycycline)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Penicillin-G-Benzathine (Type: ACTIVE_COMPARATOR): penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
- Azithromycin (Type: EXPERIMENTAL): Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)

Based on this trial design, predict the completion outcome and termination type (if applicable).